Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2009: Oral panobinostat and bortezomib for relapsed multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.03.10
Views: 10101
Rating:

Prof Jesus Fernando San-Miguel - University Hospital of Salamanca, Spain

Prof San-Miguel discusses the phase IB, multi-centre, open-label dose-escalation study of oral
pPanobinostat (LBH589) and I.V. Bortezomib in patients with relapsed multiple myeloma.

Click here to see Prof San-Miguel talking at EHA 2010 about the progression in myeloma survival rates.

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation